RxDoctor Payments Data

Juan Rodriguez, MD

Internal Medicine · Kissimmee, FLNPI 1447237292

Payments from drug & device makers

$445in general payments, 2019–2025

Across 22 payments — averaging $20.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$90
  • Boehringer Ingelheim$89
  • Novo Nordisk$71
  • Lilly USA, LLC$54
  • Amgen$53
  • Eisai Inc.$30
  • plus $59 from 3 others

What the payments were for

  • Food & beverage$445100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer5$90
Boehringer Ingelheim4$89
Novo Nordisk3$71
Lilly USA, LLC3$54
Amgen3$53
Eisai Inc.1$30
PBG Puerto Rico LLC1$21
Exact Sciences1$19
Noven Therapeutics, LLC1$18

How this compares

$445 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$8,477
Medicare patients
49
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin34$53,085
EliquisApixaban23$30,507
FarxigaDapagliflozin Propanediol27$27,636
JanuviaSitagliptin Phosphate18$27,544
XareltoRivaroxaban25$27,308
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$25,297
OzempicSemaglutide16$23,653
Breo ElliptaFluticasone/Vilanterol12$8,798
GlyxambiEmpagliflozin/Linagliptin12$5,720
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,694
Atorvastatin Calcium263$2,455
Rosuvastatin Calcium193$1,879
Metoprolol Succinate83$1,706
Levothyroxine Sodium133$1,668
Albuterol Sulfate HfaAlbuterol Sulfate58$1,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$89$58,80546 claims
PfizerEliquis$90$30,50723 claims
Novo NordiskOzempic$71$23,65316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →